UnitedHealthcare · Injectafer · US health-plan appeal rights

Injectafer denied as experimental or investigational by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Injectafer denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for injectafer are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: UHC Iron Sucrose & Ferumoxytol Policy / Injectafer PA — Step Therapy

The UnitedHealthcare angle on Injectafer

## Why UnitedHealthcare Denied Injectafer as Experimental

An experimental or investigational denial from UnitedHealthcare (UHC) means its clinical policy team determined that the evidence for Injectafer (ferric carboxymaltose) in the specific indication documented does not meet the plan's standard for established clinical benefit. UHC maintains formal Clinical Coverage Policies that define when a drug or its use is considered experimental — these policies are publicly available and are the starting point for any appeal.

This type of denial is among the most impactful to appeal, because Injectafer holds full FDA approval for defined indications. An experimental characterization applied to an on-label FDA-approved use is a factual claim that an IRO can and regularly does overturn. For off-label uses, the appeal focuses on guideline and compendium support.

## Federal Appeal Framework

ACA §2719 requires that non-grandfathered plans provide external review rights after exhausting the internal process. ERISA §503 mandates full-and-fair review for employer plans. The external-review request window is typically four months from the final denial. Expedited external review must be decided within 72 hours and is available when the standard timeline poses a health risk.

UHC is required to provide the specific clinical policy and evidence review criteria used in the denial upon request — ask for this as your first step.

## Concrete Appeal Steps

1. Request UHC's specific Clinical Coverage Policy and the evidence basis used to classify this use as experimental or investigational. 2. Confirm with your prescriber whether the use is on-label (cite the FDA-approved Injectafer label section) or off-label. 3. If on-label: the denial is directly rebutted with the label. If off-label: identify the relevant clinical guideline organization (such as ASH, ADA, ACC, or the applicable specialty society) and any recognized drug compendia that include this use. 4. Request a peer-to-peer call between your prescriber and UHC's medical director — for experimental denials, this step can prevent the need for external review. 5. Submit the internal appeal with all documentation within UHC's stated deadline. 6. If denied internally, file for external review without delay.

## Documentation to Gather

FDA prescribing label: Current Injectafer label with the applicable indication highlighted.
Prescriber clinical-necessity letter: States whether use is on- or off-label, cites the applicable guideline organization, and explains the clinical reasoning.
Diagnosis confirmation: Chart notes and objective findings establishing the diagnosis and its severity.
Prior-treatment history: Agents tried previously, with dates, doses, and documented outcomes, showing the clinical pathway leading to Injectafer.
Guideline or compendium reference (if off-label): Name of the applicable guideline organization and the relevant guidance, without citing specific statistics.

## Criteria-Mapping Structure

Obtain UHC's published Clinical Coverage Policy for IV ferric carboxymaltose and the FDA-approved Injectafer prescribing label. Build a response table:

| UHC experimental-review criterion | Supporting evidence | |---|---| | FDA approval status for this indication | [On-label: label section; or off-label with guideline org] | | Evidence of established benefit per plan standard | [Prescriber letter + guideline organization citation] | | No adequate covered alternative | [Prior-treatment history with outcomes] | | Diagnosis and clinical severity | [Chart notes, dated objective findings] |

An IRO evaluating this denial applies an independent evidentiary standard and is not bound by UHC's internal clinical policy. For an FDA-approved drug used on-label, a well-documented appeal with the label and prescriber letter has a strong track record at external review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other insurers on Injectafer

Other denial reasons for UnitedHealthcare Injectafer

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.